Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25213965 | 0.82 | MAPK1 (0.39) | ALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL25387342 | 0.77 | HDAC6 (0.53) | — | |
| SCHEMBL25267384 | 0.68 | HPGD (0.43) | ALDH1A1MAPTKDM4EGAAHPGD | |
| SCHEMBL25385533 | 0.68 | GFER (0.39) | ALDH1A1MAPTKDM4ERECQL | |
| SCHEMBL25389115 | 0.64 | HDAC6 (0.54) | — | |
| SCHEMBL12136915 | 0.62 | ALDH1A1 (0.40) | ALDH1A1MAPTKDM4EGAAHPGD | |
| SCHEMBL12519924 | 0.59 | ESR1 (0.47) | ALDH1A1MAPTKDM4EGAAHPGD | |
| SCHEMBL17828000 | 0.58 | CCR1 (0.40) | ALDH1A1MAPTKDM4EGAAHPGD | |
| SCHEMBL12692496 | 0.57 | CCR1 (0.43) | ALDH1A1MAPTKDM4EGAAHPGD | |
| SCHEMBL25160322 | 0.57 | PDE10A (0.45) | ALDH1A1MAPTKDM4EGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | ITALFARMACO SPA (IT) | 2023-09-14 | — | — | US | disclosed |
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | ITALFARMACO SPA (IT) | 2023-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | HDAC6, HDAC1, HDAC3 | ALDH1A1 980/4885MAPT 522/4885KDM4E 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.